Practice Guideline Briefs

CDC Updates 2005–2006 Influenza Vaccine Recommendations


FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.


FREE PREVIEW. Purchase online access to read the full version of this article.

Am Fam Physician. 2005 Oct 15;72(8):1613-1614.

Delays in influenza vaccine distribution or vaccine supply shortages have occurred in the United States in three of the past five influenza seasons. In previous years, prioritization was implemented to ensure the availability of vaccine for persons at the highest risk of complications from influenza. The Centers for Disease Control and Prevention (CDC) has released updated recommendations for priority use of trivalent inactivated influenza vaccine (TIV) during the 2005–2006 influenza season. Additional information is available online at http://www.cdc.gov/flu.

Four manufacturers are expected to provide influenza vaccine during the 2005–2006 influenza season (see accompanying table). Because of uncertainties about the number of available vaccine doses and the timing of distribution, the CDC recommends that the following groups be given priority to receive TIV until October 24, 2005:

• Persons 65 years and older with or without comorbid conditions

• Persons two to 64 years of age with comorbid conditions

• Children six to 23 months of age

• Residents of long-term care facilities

• Pregnant women

• Health care professionals who provide direct patient care

• Household contacts and out-of-home caregivers of children younger than six months

Starting October 24, 2005 all persons will be eligible for vaccination

The tiered use of prioritization is not recommended for LAIV administration. LAIV may be administered at any time for vaccination of nonpregnant healthy persons five to 49 years of age, including most health care professionals and other persons in close contact with groups at high risk for influenza-related complications.

View/Print Table

Influenza Vaccine Manufacturers and Projected Supply for 2005–2006 Season

Manufacturer Vaccine Formulation Contains thimerosal? Age indication Projected doses

Sanofi Pasteur, Inc.

Fluzone TIV

Multidose vial

Yes

6 months and older

60 million*

Single-dose prefilled 0.5-mL syringe or vial

No

3 years and older

Single-dose prefilled 0.25-mL syringe

No

6 to 35 months

Chiron Corp.

Fluvirin TIV

Multidose vial

Yes

4 years and older

18 to 26 Million †

Single-dose prefilled 0.5-mL syringe

No ‡

4 years and older

GlaxoSmithKline, Inc.

Fluarix TIV

Single-dose prefilled 0.5-mL syringe

No ‡

18 years and older

8 million

MedImmune Vaccines, Inc.

FluMist LAIV

Single-dose nasal sprayer

No

Healthy, nonpregnant persons 5 to 49 years of age

3 million


TIV = trivalent inactivated influenza vaccine; LAIV = live, attenuated influenza vaccine

*—Sanofi Pasteur, Inc., plans to distribute approximately 6 to 8 million of the 60 million projected doses in single-dose prefilled syringes or vials

†—Chiron Corp. plans to distribute most of its vaccine by the end of October 2005; the exact timing of distribution was uncertain as of press time. A minimal number of doses of thimerosal-free vaccine may be available late in the influenza season

‡—These preparations may contain traces of thimerosal

Adapted from Centers for Disease Control and Prevention. Update: influenza vaccine supply and recommendations for prioritization during the 2005–06 influenza season. MMWR Morb Mortal Wkly Rep 2005;54:850. Accessed online September 17, 2005, at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5434a4.htm

Influenza Vaccine Manufacturers and Projected Supply for 2005–2006 Season

Manufacturer Vaccine Formulation Contains thimerosal? Age indication Projected doses

Sanofi Pasteur, Inc.

Fluzone TIV

Multidose vial

Yes

6 months and older

60 million*

Single-dose prefilled 0.5-mL syringe or vial

No

3 years and older

Single-dose prefilled 0.25-mL syringe

No

6 to 35 months

Chiron Corp.

Fluvirin TIV

Multidose vial

Yes

4 years and older

18 to 26 Million †

Single-dose prefilled 0.5-mL syringe

No ‡

4 years and older

GlaxoSmithKline, Inc.

Fluarix TIV

Single-dose prefilled 0.5-mL syringe

No ‡

18 years and older

8 million

MedImmune Vaccines, Inc.

FluMist LAIV

Single-dose nasal sprayer

No

Healthy, nonpregnant persons 5 to 49 years of age

3 million


TIV = trivalent inactivated influenza vaccine; LAIV = live, attenuated influenza vaccine

*—Sanofi Pasteur, Inc., plans to distribute approximately 6 to 8 million of the 60 million projected doses in single-dose prefilled syringes or vials

†—Chiron Corp. plans to distribute most of its vaccine by the end of October 2005; the exact timing of distribution was uncertain as of press time. A minimal number of doses of thimerosal-free vaccine may be available late in the influenza season

‡—These preparations may contain traces of thimerosal

Adapted from Centers for Disease Control and Prevention. Update: influenza vaccine supply and recommendations for prioritization during the 2005–06 influenza season. MMWR Morb Mortal Wkly Rep 2005;54:850. Accessed online September 17, 2005, at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5434a4.htm



Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Information From Industry

More in AFP


Editor's Collections


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article